Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5

From BugSigDB


Needs review

Curated date: 2024/03/19

Curator: Ifyohondu

Revision editor(s): Ifyohondu, Victoria

Subjects

Location of subjects
Canada
United States of America
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Cohort Cohort,cohort
Group 0 name Corresponds to the control (unexposed) group for case-control studies
PIDTC Cohort (CGD Patients)
Group 1 name Corresponds to the case (exposed) group for case-control studies
NIHCC Cohort (CGD Patients)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with Chronic granulomatous disease (CGD) regardless of IBD status or antimicrobial use
Group 0 sample size Number of subjects in the control (unexposed) group
36
Group 1 sample size Number of subjects in the case (exposed) group
79
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Recent treatment with non prophylactic antibiotics (acute antibiotics)

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
increased
Chao1 Abundance-based estimator of species richness
increased

Signature 1

Reviewed Marked as Reviewed by Folakunmi on 2024-4-9

Curated date: 2024/03/19

Curator: Ifyohondu

Revision editor(s): Ifyohondu, Folakunmi

Source: Fig E4

Description: Comparison of microbiome signatures between patients with CGD (regardless of IBD status) from NIHCC and PIDTC cohorts using LEfSe

Abundance in Group 1: decreased abundance in NIHCC Cohort (CGD Patients)

NCBI Quality ControlLinks
Butyricicoccus
Streptococcus

Revision editor(s): Ifyohondu, Folakunmi

Signature 2

Reviewed Marked as Reviewed by Folakunmi on 2024-4-9

Curated date: 2024/03/19

Curator: Ifyohondu

Revision editor(s): Ifyohondu, Folakunmi

Source: Fig E4

Description: Description: Comparison of microbiome signatures between patients with CGD (regardless of IBD status) from NIHCC and PIDTC cohorts using LEfSe

Abundance in Group 1: increased abundance in NIHCC Cohort (CGD Patients)

NCBI Quality ControlLinks
Agathobacter
Clostridiales bacterium DTU089
Faecalicatena fissicatena
Monoglobus
Moryella
Oscillibacter
Sellimonas
Subdoligranulum
[Ruminococcus] torques
Incertae _SedisIncertae _Sedis
uncultureduncultured
Lachnospiraceae bacterium NK4A136

Revision editor(s): Ifyohondu, Folakunmi